Health Care & Life Sciences » Biotechnology | Charles River Laboratories International Inc.

Charles River Laboratories International Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,166
1,298
1,363
1,681
1,858
2,266
Cost of Goods Sold (COGS) incl. D&A
783
848
864
1,078
1,204
1,495
Gross Income
383
450
499
603
654
771
SG&A Expense
224
252
281
337
357
413
EBIT
159
198
218
266
297
358
Unusual Expense
7
21
17
15
14
20
Non Operating Income/Expense
1
1
4
2
16
6
Interest Expense
21
12
15
28
30
64
Pretax Income
138
178
195
223
297
282
Income Tax
33
48
43
67
171
54
Consolidated Net Income
105
130
152
156
126
227
Net Income
104
128
150
154
123
225
Net Income After Extraordinaries
105
130
151
154
124
223
Net Income Available to Common
103
127
149
155
123
226
EPS (Basic)
2.12
2.66
3.13
3.23
2.54
4.62
Basic Shares Outstanding
48
47
46
47
47
48
EPS (Diluted)
2.12
2.66
3.13
3.23
2.54
4.62
Diluted Shares Outstanding
48
48
48
48
49
49
EBITDA
255
295
313
393
428
520
Non-Operating Interest Income
1
1
1
1
1
1
Minority Interest Expense
1
2
2
2
2
2
Equity in Affiliates (Pretax)
6
9
4
-
-
-

About Charles River Laboratories International

View Profile
Address
251 Ballardvale Street
Wilmington Massachusetts 01887
United States
Employees -
Website http://www.criver.com
Updated 07/08/2019
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following business segments: Research Models & Services, Discovery & Safety Assessment, and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.